Compass therapeutics reports first quarter 2022 financial results and highlights recent company progress

Boston, may 09, 2022 (globe newswire) -- compass therapeutics, inc. (nasdaq: cmpx), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported first quarter 2022 financial results.

CMPX Ratings Summary

CMPX Quant Ranking